Physician profile
Kyle Ralston
NPI 1245891779
$3,846.60
in general payments reported to CMS, 2019-2025
17 companies · $3,697 in 2025
The $3,697 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $113 · 2024: $36.44 · 2025: $3,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,598 · Food and Beverage: $687 · Travel and Lodging: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,597.99 |
| Food and Beverage | $686.77 |
| Travel and Lodging | $561.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,078.83 | 2025 | |
| Insmed, INC. | $143.46 | 2025 | Brinsupri, Arikayce |
| Sanofi-Aventis U.S. LLC | $97.99 | 2025 | |
| Medtronic, INC. | $83.47 | 2023 | Solitaire X |
| Amgen INC. | $59.12 | 2024-2025 | Tezspire, Tavneos |
| Electromed, INC. | $50.16 | 2025 | Smartvest |
| Pulmonx Corporation | $46.33 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Genzyme Corporation | $45.16 | 2025 | |
| Lilly USA, LLC | $41.44 | 2025 | Zepbound |
| Lungpacer Medical USA INC | $39.54 | 2025 | Aeropace Neurostimulation Console |
| Glaxosmithkline, LLC. | $36.28 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Pharming Healthcare, INC. | $29.51 | 2023 | Ruconest |
| Jazz Pharmaceuticals INC. | $26.41 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $19.54 | 2025 | Lumryz |
| Astrazeneca Pharmaceuticals LP | $17.57 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.13 | 2025 | |
| Verona Pharma, INC. | $14.66 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Ralston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.